BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21711395)

  • 1. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
    Falco P; Levis A; Stacchini A; Ciriello MM; Geuna M; Notari P; Omedè P; Pautasso M; Prato G; Strola G; Gioia D; Bonferroni M; Cametti G; Ferrero D; Freilone R; Gaidano G; Marinone C; Marmont F; Pollio B; Salvi F; Saglio G; Girotto M;
    Eur J Haematol; 2011 Nov; 87(5):409-18. PubMed ID: 21711395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
    Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
    Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
    Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
    Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface marker abnormalities in myelodysplastic syndromes.
    Elghetany MT
    Haematologica; 1998 Dec; 83(12):1104-15. PubMed ID: 9949628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
    Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
    Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome.
    Font P; Subirá D; Mtnez-Chamorro C; Castañón S; Arranz E; Ramiro S; Gil-Fernández JJ; López-Pascual J; Alonso A; Pérez-Sáenz MA; Alaez C; Renedo M; Blas C; Escudero A; Fdez-Rañada JM
    Leuk Res; 2006 Aug; 30(8):957-63. PubMed ID: 16417922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):234-8. PubMed ID: 21418866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
    Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
    Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
    Wang H; Wang XQ; Xu XP; Lin GW
    Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry.
    Huang M; Li J; Zhao G; Sui X; Zhao X; Xu H
    Int J Lab Hematol; 2010 Jun; 32(3):275-81. PubMed ID: 19968721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
    Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.